Author/Authors :
Haytoglu, Zeliha Çukurova Üniversitesi - Tıp Fakültesi - Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Turkey , Karagün, Barbaros Çukurova Üniversitesi - Tıp Fakültesi - Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Hematoloji ve Onkoloji bölümü, Turkey , Antmen, Bülent Çukurova Üniversitesi - Tıp Fakültesi - Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Hematoloji ve Onkoloji bölümü, Turkey , Şaşmaz, İlgen Çukurova Üniversitesi - Tıp Fakültesi - Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Hematoloji ve Onkoloji bölümü, Turkey , Kılınç, Yurdanur Çukurova Üniversitesi - Tıp Fakültesi - Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Hematoloji ve Onkoloji bölümü, Turkey
Abstract :
Purpose: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a TNF superfamily member. TRAIL is transmembrane protein expressed on cell surfaces and has a broad expression pattern in a variety of organs. Cleavage of its C-terminal part (extracellular domain) allows for a soluble form of TRAIL.TRAIL induces apoptosis with its receptors TRAIL-receptor 1 (TRAIL-R1), TRAIL-receptor 2 (TRAIL-R2) however apoptosis can not be induced by receptors TRAIL-receptor 3 (TRAIL-R3) and TRAIL-receptor 4 (TRAIL-R4). There are many trials to search the correlation between leukemia and apoptotic pathway disorders. In this study we determined the seum levels of TRAIL in acute childhood leukemias at first diagnose. We aimed to determine the relation between the levels of serum TRAIL and patient’s survey, clinical parameters. Material and Methods: The study was performed in patients admitted to Pediatric Hematology and Pediatric Oncology Department of Çukurova University Medical Faculty between October 2009 and July 2010. Twenty-three cases with new diagnosis acute lymphoblastic leukemia (ALL) at the age disturbition 9-months-12-year and 8-months and fourteen cases with new diagnosis acute myeloblastic leukemia (AML) at the age disturbition of 9 days-18 years are included in this study. Twenty-one healty children with no blood disease with similar sex and age with leukemia group was chosen as the control group. Serum TRAIL levels were determined by using ELISA method. Results: The comparison of the average values of the TRAIL levels in acute leukemia patients and control group have shown that patients with leukemia have low serum TRAIL levels (p=0.002). In patients with high-risk-grade (HRG) of ALL compared with control group have shown low serum TRAIL levels in HRG of ALL (p=0.008). In patients with common acute lymphoblastic leukemia antigen(CALLA)(- ) B ALL compared with control group have shown low serum TRAIL levels in CALLA(-) B ALL (p=0.004). Children with acute leukemias (ALL, AML) who died during treatment compared with survived group have shown low levels of serum TRAIL in expired patients (p=0.004). Conclusion: As a result, serum TRAIL might play a role in leukomegenesis. The low levels of serum TRAIL detected in our patients may be associated with leukomogenezis and impaired TRAIL-mediated apoptosis. To suggest soluble TRAIL’s role in acute leukemias detection of TRAIL-mediated apoptosis is needed. The low serum TRAIL may be used as a sign of bad prognosis. For more comphrensive results prospective studies with greaater number of patients are needed.
